Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking strategy to diabetes management. These innovative therapies operate by mimicking the inherent actions of GLP-1, a hormone released by the gut in response to meals. By activating GLP-1 receptors in the pancreas, these substances boost insulin secretion and suppress glu

The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a alike therapeutic goal – improving glycemic control and promoting substantial weight decrease – they exhibit intriguing contrasts in their pha